Table 1 Demographics, distribution of clinical risk factors in healthy subjects (HS), patients with pancreatic cancer (PC), intraductal papillary mucinous neoplasm (IPMN), and chronic pancreatitis (CP), and baseline clinical-pathological features of patients with PC.
From: Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer
HS (N = 267) | PC (N = 167) | IPMN (N = 19) | CP (N = 20) | |
|---|---|---|---|---|
Age, median (Q1–Q3) | 60 (54–69) | 68 (61–76) | 73 (64–75.5) | 54 (47–62.5) |
<55 years, N (%) | 70 (26.2) | 23 (13.8) | 1 (5.3) | 11 (55) |
≥55 years, N (%) | 197 (73.8) | 144 (86.2) | 18 (94.7) | 9 (45) |
Gender, N (%) | ||||
Male | 116 (43.4) | 86 (51.5) | 8 (42.1) | 14 (70) |
Female | 151 (56.6) | 81 (48.5) | 11 (57.9) | 6 (30) |
Body Mass Index, median (Q1–Q3) | 27 (24–30) | 25 (23–28) | 27 (26.1–28.1) | 23.2 (20.4–27) |
≤30, N (%) | 204 (76.4) | 138 (85.2) | 16 (84.2) | 17 (85) |
>30, N (%) | 63 (23.6) | 24 (14.8) | 3 (15.8) | 3 (15) |
Smoker, N (%) | ||||
No | 133 (49.8) | 71 (42.5) | 13 (68.4) | 4 (20) |
Current/past | 134 (50.2) | 96 (57.5) | 6 (31.6) | 16 (80) |
Alcohol abuse (≥3 drinks a day), N (%) | ||||
No | 250 (93.6) | 151 (91) | 7 (36.8) | 5 (25) |
Yes | 17 (6.4) | 15 (9) | 12 (63.2) | 15 (75) |
Diabetes, N (%) | ||||
No | 230 (86.1) | 102 (61.6) | 13 (68.4) | 12 (60) |
Yes | 37 (13.9) | 65 (38.9) | 6 (31.6) | 8 (40) |
Family history of cancer, N (%) | ||||
No | 70 (26.3) | 57 (35.4) | 10 (52.6) | 6 (30) |
Yes | 196 (73.7) | 104 (64.6) | 9 (47.4) | 14 (70) |
Tumor location, N (%) | ||||
Head | 117 (71) | |||
Body | 21 (13) | |||
Tail | 27 (16) | |||
Pre-operative classification, N (%) | ||||
Resectable | 34 (20) | |||
Locally advanced | 60 (36) | |||
Metastatic | 73 (44) | |||
Surgery, N (%) | ||||
No | 138 (83) | |||
Yes | 29 (17) | |||
Tumor stage, N (%) | ||||
IB | 1 (0.6) | |||
IIA | 4 (2.5) | |||
IIB | 25 (15.7) | |||
III | 56 (35.2) | |||
IV | 73 (45.9) | |||
Adjuvant therapy, N (%) | ||||
No | 63 (39) | |||
Yes | 100 (61) | |||
